Science

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee/X

Mar 4, 2025, 05:22

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

Rahul Banerjee, Assistant professor at Fred Hutchinson Cancer Center at the University of Washington, shared an article by Luciano J Costa, et al. on X:

“Yesterday I learned that teclistamab & talquetamab are approved in Mexico for triple-class exposed Multiple Myeloma regardless of lines of therapy Love this!

So much more practical and scientifically sound. Some day we’ll be able to ditch LOT, and it’ll be our LMIC colleagues leading the charge!”

Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma.

Authors: Luciano J Costa, et al.

Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed

cancer fight against cancer Fred Hutchinson Cancer Center Global fight against cancer LMIC Luciano J Costa Mexico multiple myeloma OncoDaily Oncology Rahul Banerjee Talquetamab teclistamab University of Washington

Val Kilmer Dies at 65: The Actor Who Fought Throat Cancer and Inspired Generations

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

Highlights from ELCC 2025

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

Meet the New AACR Board of Directores for 2025-2028 Term